This should be the easiest job for Msb as the product was successfully demonstrated to the Covud-19 ARD patients.
FDA gave Msb a chance to market its products to treat both Covid-19 ARD and GVHD related patients in both adults and children.
The enrollment numbers will rise when ill-fated patients on ventilators witness the recovery rates on the registered patients.
One arrow will bring down two ducks.
The sp will rise 100%
Ann: Phase 3 Trial in COVID-19 ARDS Surpasses 50% Enrollment, page-107
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
0.045(3.33%) |
Mkt cap ! $1.592B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.42 | $1.33 | $3.802M | 2.753M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 23940 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 22571 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |